Implementation of the Stem Cell Therapeutic and Research Act of 2005

Similar documents
Re-Envisioning OPTN/UNOS: HRSA Role as a Force for Innovation in Organ Transplantation

AMERICA S HEALTH CARE SAFETY NET

Update of The National Vaccine Plan

HRSA Oral Health Programs 2010 Dental Management Coalition June 27, 2010 Annapolis, MD

Proposed Maternal and Child Health Funding Highlights Fiscal Year 2013 Senate Labor, Health and Human Services Appropriations

AAPD 2018 Legislative and Regulatory Priorities Council on Government Affairs Approved by the Board of Trustees on January 12, 2018

AABB Standards and Accreditation. Doug Padley, MT (ASCP) Mayo Clinic Rochester MN USA

Ryan White Part A Overview

S Congenital Heart Futures Act (Introduced in Senate - IS) 111th CONGRESS 1st Session S. 621 IN THE SENATE OF THE UNITED STATES.

Title: SECTION 7.0 NZBMDR STANDARDS PROCESS FOR DONOR IDENTIFICATION

TA L K I N G A B O U T T R A N S P L A N TAT I O N UNOS. Facts and. Figures

For An Act To Be Entitled. Subtitle

FY2019 Labor, Health and Human Services, Education Appropriations Summary

TRAUMA RECOVERY/HAP OPERATING GUIDELINES

Legislative Counsel s Digest:

What are the goals of the NJHPG?

About OMICS Group Conferences

AAPD 2017 Legislative and Regulatory Priorities Council on Government Affairs Approved by the Board of Trustees on January 13, 2017

NATIONAL MARROW DONOR PROGRAM. Creating Connections. Saving Lives. Fran Rabe

Report on the Transplantation Transmission Sentinel Network (TTSN)

Some groups or issues identified as "at risk for" or "affected by" HIV in Southern Nevada are:

HRSA TECHNICAL ASSISTANCE (TA) OUTREACH INITIATIVE

What are the goals of the NJHPG?

Oral Health Provisions in Recent Health Reform: Opportunities for Public-Private Partnerships

Cord Blood Bankers are. Angie Yost, MT(ASCP) CM 2016 ASCLS-MO CLMA Spring Meeting

Progenics Cord Blood Cryobank Monthly Quality Report

The TTSN - A Collaborative Biovigilance System

National Vaccine Injury Compensation Program: Adding the Category of Vaccines. AGENCY: Health Resources and Services Administration (HRSA), HHS.

Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;

Department of Legislative Services

REPORT OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH. AMA Policy Consolidation: Influenza and Influenza Vaccine

One Hundred Ninth Congress of the United States of America

Relevant Communicable Diseases in HCT/Ps

Zika Virus. Report to the Standing Committee on Health. Dr. Graham Sher Chief Executive Officer, Canadian Blood Services

COOPERATIVE AGREEMENTS FOR STATE-BASED COMPREHENSIVE BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAMS

STATE OF NEW JERSEY. SENATE, No th LEGISLATURE. Sponsored by: Senator JAMES W. HOLZAPFEL District 10 (Ocean)

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

US Proposal to Transform Response to Hepatitis B and C. Anna S. F. Lok, MD University of Michigan Ann Arbor, MI, USA

H. R To amend the Public Health Service Act with respect to pain care. IN THE HOUSE OF REPRESENTATIVES

Perspective from HHS Offices and Programs on Women s s Health: FDA Perspective

The Value of Community- Based Initiatives

Ryan White HIV/AIDS Part C Capacity Development Program

DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality

RYAN WHITE HIV/AIDS PROGRAM PART A PLANNING COUNCIL PRIMER

Progress from the Patient-Centered Outcomes Research Institute (PCORI)

The Ryan White Comprehensive AIDS Resources Emergency (CARE) Act: A Side-by-Side Comparison of Current Law and Reauthorization Proposals

Opportunities for Organ Donor Intervention Research

Clinical Quality Management Policy Clarification Notice

S. ll IN THE SENATE OF THE UNITED STATES A BILL

2015 Exam Committees Report for the National Physical Therapy Examination Program

By Laws: Spinal Cord Injury Research Fund Board Board Approval May 2, 2014

Guidance for Industry

Guidance for Industry

Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low

Secretary's Advisory Committee on Heritable Disorders in Newborns and Children May 13, 2009

Global Perspective on Donor and Recipient Safety: Biovigilance in Hematopoietic Cell Transplantation

System-level Workforce Capacity Building for Integrating HIV Primary Care in Community Health Care Settings Evaluation and Technical Assistance Center

April 24, testimony. The AGS is a non-profit organization of nearly 6,000 geriatrics healthcare

Update on Florida Medicaid Dental Performance

Secretary of the Senate. Chief Clerk of the Assembly. Private Secretary of the Governor

Program Priorities 2018

The National Kidney Foundation (NKF) is pleased to submit testimony regarding the impact of

CHAPTER 2 NETWORK PROVIDER/SERVICE DELIVERY REQUIREMENTS

Seventy percent of people who are candidates for allogeneic hematopoietic

STATE AND COMMUNITY MODELS FOR IMPROVING ACCESS TO DENTAL CARE FOR THE UNDERSERVED

Documentation of Changes to EFI Standards: v 5.6.1

The National Vaccine Advisory Committee: Reducing Patient and Provider Barriers to Maternal Immunizations

Canadian HIV/AIDS Pharmacists Network. Association Canadienne des Pharmaciens en VIH/SIDA. Terms of Reference

Center for Biologics Evaluation and Research

Amendment 72 Increase Cigarette and Tobacco Taxes

Health Care Reform: Implications for Public Health. Susan Polan, PhD. American University Next steps in Health Reform 2017

Patricia Ward Chief Budget Officer (919)

CRS Report for Congress

Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care

2/26/2016. Types of Stem Cells: Agenda. Objectives

CHAPTER Section 1 of P.L.1999, c.105 (C.30:6D-56) is amended to read as follows:

SENATE, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 8, 2016

Why Policy Matters. Making the Case for Rural Health and Wellness. Paul Moore, DPh Senior Health Policy Advisor Federal Office of Rural Health Policy

Strategies for Federal Agencies

Ryan White HIV/AIDS Part C Capacity Development Program Pre-Application Technical Assistance Conference Call HRSA March 12, 2015

REGULATORY IMPACT STATEMENT and COST-BENEFIT ANALYSIS (RISCBA)

June 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

The Murphy Bill in 2015

Strategies to Improve Viral Hepatitis Prevention, Care and Treatment through Appropriations. Emily McCloskey USCA October 3, 2014

Opioid Response Package Awaits President s Signature Trinity Tomsic

AUGUST 200 JULY Reauthorization of PEPFAR, The United States Leadership Against HIV/AIDS, Tuberculosis and Malaria Act:

Dental Public Health Activities & Practices

Federation of State Boards of Physical Therapy

23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

DEPARTMENT OF HEALTH AND SENIOR SERVICES PO BOX 360 TRENTON, N.J

Haplo vs Cord vs URD Debate

CRS Report for Congress

2014 U.S. organ and tissue transplant cost estimates and discussion

REGIONAL SPECIALIZED GERIATRIC SERVICES GOVERNANCE AUTHORITY. Call for Expressions of Interest from Seniors Advocate/Public Member

ACIP Developing Vaccine Recommendations and Policy in the US

Getting Emerging Planning Professionals Started: What We re All About. Draft for Discussion

US H.R.6 of the 115 th Congress of the United States Session

ANALYSIS OF THE ADMINISTRATION S FISCAL YEAR 2004 BUDGET FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION

IOWA COALITION ON MENTAL HEALTH AND AGING. Policy and Administration Workgroup

Transcription:

Implementation of the Stem Cell Therapeutic and Research Act of 2005 The 6 th Annual Somatic Cell Therapy Symposium Bethesda, MD September 26, 2006 James F. Burdick, M.D. U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Division of Transplantation

Presentation Outline Information about HRSA Stem Cell Therapeutic and Research Act of 2005 - Background & Overview HRSA s Implementation Approach Focus on 3 Program Components: National Cord Blood Inventory Cord Blood Coordinating Center Advisory Council Future Work

Health Resources and Services Administration (HRSA) Mission: HRSA provides national leadership, program resources and services needed to improve access to culturally competent, quality health care HRSA focuses on uninsured, underserved, and special needs populations HRSA Goals Goal 1: Improve Access to Health Care Goal 2: Improve Health Outcomes Goal 3: Improve the Quality of Health Care Goal 4: Eliminate Health Disparities Goal 5: Improve the Public Health and Health Care Systems Goal 6: Enhance the Ability of the Health Care System to Respond to Public Health Emergencies Goal 7: Achieve Excellence in Management Practices

Health Resources and Services Administration, continued HRSA Programs include: Community Health Centers HIV services under the Ryan White CARE Act Maternal and Child Health Programs Health Professions Development Programs National systems to facilitate transplantation: Solid Organs Organ Procurement & Transplantation (UNOS) Scientific Registry of Transplant Recipients (URREA) Blood Stem Cells National Bone Marrow Donor Registry (NMDP) Stem Cell Therapeutic and Research Act of 2005

Stem Cell Therapeutic and Research Act of 2005 (P.L. 109-129) Authorizing law, preceded by efforts to: Enact authorizing legislation for collection and distribution of cord blood units (CBU) Re-authorize the National Bone Marrow Donor Registry Appropriations for a National Cord Blood Stem Cell Bank Program, FY 2004-2006 2004 Conference Report required an Institute of Medicine (IOM) study; report issued April 14, 2005 Appropriations totaled nearly $24 million (including $1 million specified for IOM study)

P.L. 109-129, continued Signed December 20, 2005 Aims are to increase: Number of unrelated donor transplants Public inventory of high quality CBU from diverse populations Number of CBU available for research Very exciting opportunity to help more patients obtain transplants, other therapy

P.L. 109-129, continued Four Sections Sec.1: Short Title Sec.2: National Cord Blood Inventory Sec.3: C.W. Bill Young Cell Transplantation Program (the Program) Sec.4: Report on status of FDA Licensure of CBU

P.L. 109-129: Section 2 National Cord Blood Inventory (NCBI) HRSA funding for high quality, diverse CBU Target of 150,000 new units Authorizes appropriations of $15 million/year, FY 2007-2010 Federal funding temporary until 150,000 CBU Funding structure: One-time contracts Federal funding limited to 3 years CBB must participate in the Program for 10 years NCBI CBU must be available through the Program in perpetuity Related CB Demonstration, FY 2007-2009 Some CBU not appropriate for transplantation to be available for research

P.L. 109-129: Section 3 C.W. Bill Young Cell Transplantation Program (successor to National Bone Marrow Donor Registry) Provides the infrastructure for the Program Facilitation of transplants and outcomes data collection Up to 5 components established by HRSA contracts Advisory Council at HHS level Provisions regarding accrediting organization(s) for CBB, informed consent for donating CBU Federal funding intended to be ongoing Authorizes $38 million/year, FY 2007-2010 Approximately $25 million available in FY 2006

Program Components Department of Health and Human Services Advisory Council HRSA/Division of Transplantation Accrediting Organizations Cord Blood Banks Cord Blood Coordinating Center Outcomes Database Bone Marrow Coordinating Center Blood Stem Cell Single Point of Access Office of Patient Advocacy Possible New HRSA Contract Organizations Other New Organizations or Relationships Transplant Centers Patients Referring Physicians

HRSA s Implementation Approach Guided by three principles: Single Point of Access for patients and physicians to all sources of blood stem cells Collection of high-quality diverse CBU, expeditiously Complete data on clinical outcomes of transplants Recognizes field is evolving rapidly Informed by extensive consultation: Request for Information published August 15, 2005 Teleconferences with transplant physicians Consultation with reps. of ASBMT Teleconferences with public and private CBB

HRSA s Implementation Approach, continued Consultation, continued Site visits to public and private cord blood banks Teleconferences on informed consent Correspondence with accrediting organizations Teleconferences on accreditation (announced in Federal Register) Discussions with experts in CBU processing Consultation with other Federal agencies (e.g., NIH, FDA, CDC) Congressional briefings

HRSA s Implementation Approach, continued Parallel establishment of program components Contract components - competitive contracts Cord Blood Banks to collect NCBI Infrastructure components Advisory Council Accrediting Organization(s) During transition, HRSA will extend National Bone Marrow Donor Registry contract To ensure continuity of service

HRSA s Implementation Approach, continued Contract awards by 9/30/06 require interim approaches to: Technical requirements for CBB and HRSAfunded CBU Recognition of accrediting organization(s) Requirements regarding informed consent Interim provisions to be revisited in future years, with Advisory Council and public input

HRSA s Implementation Approach, continued The following schematic shows the contract structure for the program Does not show relationships for: Facilitating transplants Reporting Outcomes Data Program oversight

C.W. Bill Young Cell Transplantation Program: Contracting Structure Department of Health and Human Services $ HRSA/Division of Transplantation Advisory Council $ $ $ $ $ Accrediting Organizations Infrastructure Cord Blood Banks Cord Blood Coordinating Center Outcomes Database Bone Marrow Coordinating Center Public Interface Blood Stem Cell Single Point of Access Access Point for Stem Cell Sources Patient Advocacy Services HRSA Contract Organizations Other New Organizations or Relationships Transplant Centers Patients Referring Physicians

National Cord Blood Inventory: Highlights of HRSA Approach Banks funded through one-time, 10-year contracts, awarded competitively HRSA funds for 3 years Annual competitions for new cohorts of banks Add banks in new geographic areas fine-tune diversity of NCBI Permit funding new banks w/o long wait for funding opportunity Broaden the opportunity for Federal support Encourage improvement in quality across the industry Permit timely adjustments based on bank performance Available funds: ~ $14M for FY 2006; ~ $8M for FY 2007 HRSA reimbursement at fixed rate per unit, for X units HRSA expects to negotiate discounted prices necessary to make progress toward 150,000 units

National Cord Blood Inventory: Highlights of HRSA Approach, continued Interim technical requirements for NCBI (HRSA reimbursable) CBU include: Total nucleated cell count (TNC) 90 x 10 7 (without subtraction of nucleated red blood cells) CFU-GM assay must show growth TNC Viability 85% CD34+ content / viability measured no min. value At least 2 attached segments Negative for: infectious disease markers, bacteria and fungi, and clinically significant hemoglobinopathies Minimum human leukocyte antigen (HLA) typing: low/intermediate resolution @ A,B; high @ DR; all by DNA methods

National Cord Blood Inventory (NCBI): Highlights of HRSA Approach, continued Bank eligibility requirements include: Accreditation by an organization recognized by the Secretary Pending such recognition, accreditation by FACT or AABB Minimum public inventory of 500 CBU collected and banked by the CBB Request for Proposals (RFP) Issued April 28, 2006 Proposals received June 5, 2006 Awards to be made by ~September 30, 2006

Cord Blood Coordinating Center (CBCC): Highlights of HRSA Approach Functions include: Facilitate transplants with CBU from NCBI banks (NCBI CBU, Other CBU) Other participating banks Provide standardized search information on CBU to the Single Point of Access Facilitate further testing of CBU being evaluated for a patient Facilitate distribution of CBU Require submission of outcomes data Assist banks in public education and recruitment

Cord Blood Coordinating Center (CBCC): Highlights of HRSA Approach, continued Functions, continued: Coordinate contingency planning with banks Coordinate inter-bank proficiency testing program Compile data on CBU released for research RFP (published May 23, 2006) does not prescribe or prohibit a particular model or technology, consistent with Congressional direction RFP allows for subcontracting and consortia arrangements CBCC operating policy/procedures subject to HRSA approval CBCC will coordinate with other Program components through several working groups

Advisory Council Purpose Consider and make recommendations to the Secretary on matters related to the Program Steps in establishment under Federal Advisory Committee Act (FACA) include Draft & Final establishment packages to HHS Publish charter and call for nominations in the Federal Register Draft & Final Nomination Packages to HHS Secretary appoints members Announce first meeting in the Federal Register

Advisory Council, continued Membership Statute lists 15 required categories voting and non-voting ex officio members Other categories recommended to HRSA in RFI responses Number and categories of members will be specified in Federal Register Notice

Advisory Council, continued Statutory membership categories: Voting members: Reps of marrow donor centers and marrow transplant centers Reps of cord blood banks and participating birthing hospitals Recipients of bone marrow transplant Recipients of cord blood transplant Persons who require such transplants Family members of a recipient or a patient who has requested the assistance of the Program in searching for an unrelated donor of bone marrow or cord blood Persons with expertise in bone marrow and cord blood transplantation Persons with expertise in typing, matching, and transplant outcome data analysis Persons with expertise in the social sciences Basic scientists with expertise in the biology of adult stem cells Members of the general public Non-voting, ex-officio members: HRSA, FDA, NIH, DoD

Advisory Council, continued Other membership categories suggested to HRSA: Voting Members Representatives from transplant centers with extensive experience in unrelated donor transplants, including cord blood transplants Hematology and transfusion medicine researchers with expertise in adult stem cells from adult donors and cord blood Ethicists Experts in Obstetrics Experts in Cord Blood Processing Experts in Bio-informatics Representatives from Accreditation Programs Donor and Donor Representatives (family members of cord blood and adult donors) Non-voting, ex-officio members: CMS, CDC

Advisory Council, continued Possible Topics for Advisory Council: Targets for National Cord Blood Inventory & Adult Registry size & composition Research Priorities HPC transplantation Other therapy with cells from CB & BM Criteria for units for research CBU characteristics needed for good outcomes Criteria for choosing best stem cell source

Advisory Council, continued Possible Topics for Advisory Council: Program priorities based on reports of activity and performance Public & Professional Education - re donation Regulatory Policy including international harmonization of regulation Public and Private Insurers actions to increase donation and access to transplant State and Federal Government - actions (other than as insurers)

Some Work Beyond September Complete transition to new program structure Complete establishment of Advisory Council Revisit interim program requirements, with Advisory Council and public input, esp. re Accreditation Informed Consent Definition of a high-quality CBU Define targets for composition of NCBI, and size & composition of adult donor registry, in consultation with Advisory Council

Some Work Beyond September, continued Design & begin the Related Cord Blood Demonstration Project Future cycles of funding for CB banks Encourage research, in collaboration with other Federal agencies and Advisory Council, to, e.g.: Improve transplant outcomes CB and adult donor Refine approaches to CB transplants for adult patients Better define CBU characteristics required for good outcomes Improve reliability and comparability of measures used in CBU selection Collect and report data re new uses of stem cells from CBU and adult donors

References Stem Cell Therapeutic and Research Act of 2005 (P.L. 109-129) http://frwebgate.access.gpo.gov/cgibin/getdoc.cgi?dbname=109_cong_public_laws&docid=f:publ129.109.pdf Senate Report http://frwebgate.access.gpo.gov/cgibin/getdoc.cgi?dbname=109_cong_reports&docid=f:sr129.109.pdf IOM Report http://darwin.nap.edu/books/0309095867/html/ National Cord Blood Inventory - Request for Proposals http://www.fbo.gov/spg/hhs/hrsa/dgpm/06%2dn234%2d5504/attachments.h tml Cord Blood Coordinating Center Request for Proposals http://www2.fbo.gov/spg/hhs/hrsa/dgpm/06%2dn234%2d5507%2dam/listin g.html

THANK YOU for your attention QUESTIONS?

My Contact Information James F. Burdick 5600 Fishers Lane, Room 12C-06 Rockville, Maryland 20857 301-443-7577 JBurdick@hrsa.gov